logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Huntington Potter

This inventor holds 12 USPTO granted patents. Top assignee: Harvard College. Active years: 1986-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Huntington Potter. Retrieved from https://idiyas.com/inventor/huntington-potter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12

% Patents Active = 100.0

Average Co-Inventor Count = 1.3

ph-index = 7

Forward Citations = 188(Granted Patents)


Location History:

  • Somerville, MA (US) (1986)
  • Boston, MA (US) (1993 - 2002)

Company Filing History:

goldMedal12 out of 3,075 
 
Harvard College
 patents

Years Active: 1986-2002

Loading Chart...
12 patents (USPTO):Explore Patents
1. 6444870 - Methods for assessing the role of calcineurin immunosuppression and neurotoxicity (2002-09-03),
2. 6214569 - Methods for screening for inhibitors of Alzheimer &bgr;-peptide filament formation (2001-04-10),
3. 5985564 - Assay for identifying agents that inhibit chromosome non-disjunction (1999-11-16),
4. 5780587 - Compounds and methods for inhibiting .beta.-protein filament formation (1998-07-14),
5. 5778893 - Method of diagnosing and monitoring a treatment for Alzheimer's disease (1998-07-14),
6. 5571671 - Method for detecting alzheimer's disease (1996-11-05),
7. 5535760 - Method for detecting and treating Alzheimer's disease (1996-07-16),
8. 5506097 - Method for inhibiting .beta.-protein enzymatic activity (1996-04-09),
9. 5338663 - Method of identifying inhibitors of .beta.-protein esterase activity (1994-08-16),
10. 5297562 - Method for detecting and treating Alzheimer's disease (1994-03-29),
11. 5229365 - Endocrine cell stimulation by neurotrophic agents (1993-07-20),
12. 4613566 - Hybridization assay and kit therefor (1986-09-23),

Title: Huntington Potter: Innovator in Neuropharmacology

Introduction

Huntington Potter is a prominent inventor based in Boston, MA (US), known for his significant contributions to neuropharmacology. He holds a total of 12 patents, focusing on methods related to immunosuppression and neurotoxicity, particularly in the context of Alzheimer's disease.

Latest Patents

Among his latest patents, Potter has developed methods for assessing the role of calcineurin immunosuppression and neurotoxicity. This invention relates to identifying drugs or agents that exhibit immunosuppressive effects through their impact on calcineurin. It includes drugs that affect the calcineurin Aα (CNAα) and calcineurin Aβ (CNAβ) subunits. Additionally, he has created methods for identifying drugs that reduce the phosphorylation of tau protein and the formation of paired helical filaments in the nervous system of mammals. Another notable patent involves methods for screening inhibitors of Alzheimer β-peptide filament formation, which can be used to treat individuals with Alzheimer's disease by administering compounds that interfere with the interaction between Alzheimer β-protein and Apolipoprotein E4 or α-antichymotrypsin.

Career Highlights

Huntington Potter is affiliated with Harvard College, where he conducts research and develops innovative solutions to complex neurological issues. His work has garnered attention in the scientific community, contributing to advancements in understanding and treating neurodegenerative diseases.

Collaborations

Potter has collaborated with notable colleagues, including Usamah Kayyali and Wei Zhang, to further his research and enhance the impact of his inventions.

Conclusion

Huntington Potter's innovative work in neuropharmacology and his numerous patents highlight his commitment to advancing medical science and improving treatment options for Alzheimer's disease. His contributions continue to shape the future of neuropharmacological research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…